Bone metabolic markers, TRAP, and Zometa's effect on bone metastasis due to lung cancer.

Trial Profile

Bone metabolic markers, TRAP, and Zometa's effect on bone metastasis due to lung cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Cancer metastases; Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2011 Planned end date changed from 1 Dec 2008 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 14 Apr 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Actual patient number (28) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top